Cargando…

PRL-3 facilitates Hepatocellular Carcinoma progression by co-amplifying with and activating FAK

Background: In addition to protein tyrosine kinases, accumulating evidence has shown that protein tyrosine phosphatases (PTPs) are suitable therapeutic targets in cancer. PRL-3 is a PTP member that has been well studied in many malignant tumours. The goal of the present study was to elucidate the ro...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Qiming, Zhou, Qianlei, Liu, Qinghua, He, Zhanghai, Yan, Yongcong, Lin, Jianhong, Chen, Zheng, He, Chuanchao, Mao, Kai, Wang, Jie, Zhou, Zhenyu, Xiao, Zhiyu, Zhang, Jianlong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7481414/
https://www.ncbi.nlm.nih.gov/pubmed/32929353
http://dx.doi.org/10.7150/thno.42069
_version_ 1783580598402547712
author Zhou, Qiming
Zhou, Qianlei
Liu, Qinghua
He, Zhanghai
Yan, Yongcong
Lin, Jianhong
Chen, Zheng
He, Chuanchao
Mao, Kai
Wang, Jie
Zhou, Zhenyu
Xiao, Zhiyu
Zhang, Jianlong
author_facet Zhou, Qiming
Zhou, Qianlei
Liu, Qinghua
He, Zhanghai
Yan, Yongcong
Lin, Jianhong
Chen, Zheng
He, Chuanchao
Mao, Kai
Wang, Jie
Zhou, Zhenyu
Xiao, Zhiyu
Zhang, Jianlong
author_sort Zhou, Qiming
collection PubMed
description Background: In addition to protein tyrosine kinases, accumulating evidence has shown that protein tyrosine phosphatases (PTPs) are suitable therapeutic targets in cancer. PRL-3 is a PTP member that has been well studied in many malignant tumours. The goal of the present study was to elucidate the role of PRL-3 in hepatocellular carcinoma (HCC), which remains largely unknown. Methods: Bioinformatic and immunohistochemical analyses were performed to analyse PRL-3 expression in HCC tissue samples and determine its clinical relevance. PRL-3 gene copy number variations were evaluated by bioinformatic analysis and quantitative-genomic polymerase chain reaction. The biological functions of PRL-3 were investigated in vivo and vitro. Gene microarray assays, RT-qPCR, western blotting and luciferase experiments were performed to identify the downstream effectors of PRL-3 that mediate its functions in HCC. Results: PRL-3 expression was upregulated in HCC samples from public databases and in cohort samples from our centre. High PRL-3 expression was associated with poor prognosis. Copy number gains and amplification of chromosome 8q24.3 in HCC were determined to be positively correlated with the PRL-3 overexpression. PRL-3 overexpression promoted HCC cell proliferation, migration and adhesion, while its loss had the opposite effects. Further study showed that focal adhesion kinase (FAK) was co-amplified and co-expressed with PRL-3 in HCC. Interestingly, PRL-3 also promoted the phosphorylation of FAK, which subsequently mediated the oncogenic functions of PRL-3 in HCC cells. Moreover, TGFB1 was identified as a downstream molecule of PRL-3. TGF-β signalling was shown to mediate the PRL-3-induced activation of FAK. Furthermore, the p38 and PI3K/AKT pathways were observed to mediate the PRL-3-induced expression of TGFB1 and the subsequent activation of FAK, while the activation of FAK in turn stimulated activation of the p38 and PI3K/AKT pathways, forming a PRL-3-triggered AKT/p38/TGFB1/FAK positive feedback loop. Conclusion: Collectively, our findings indicate that the PTP PRL-3 plays a crucial role in the progression of HCC and provides an example of how co-amplified genes work together in HCC.
format Online
Article
Text
id pubmed-7481414
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-74814142020-09-13 PRL-3 facilitates Hepatocellular Carcinoma progression by co-amplifying with and activating FAK Zhou, Qiming Zhou, Qianlei Liu, Qinghua He, Zhanghai Yan, Yongcong Lin, Jianhong Chen, Zheng He, Chuanchao Mao, Kai Wang, Jie Zhou, Zhenyu Xiao, Zhiyu Zhang, Jianlong Theranostics Research Paper Background: In addition to protein tyrosine kinases, accumulating evidence has shown that protein tyrosine phosphatases (PTPs) are suitable therapeutic targets in cancer. PRL-3 is a PTP member that has been well studied in many malignant tumours. The goal of the present study was to elucidate the role of PRL-3 in hepatocellular carcinoma (HCC), which remains largely unknown. Methods: Bioinformatic and immunohistochemical analyses were performed to analyse PRL-3 expression in HCC tissue samples and determine its clinical relevance. PRL-3 gene copy number variations were evaluated by bioinformatic analysis and quantitative-genomic polymerase chain reaction. The biological functions of PRL-3 were investigated in vivo and vitro. Gene microarray assays, RT-qPCR, western blotting and luciferase experiments were performed to identify the downstream effectors of PRL-3 that mediate its functions in HCC. Results: PRL-3 expression was upregulated in HCC samples from public databases and in cohort samples from our centre. High PRL-3 expression was associated with poor prognosis. Copy number gains and amplification of chromosome 8q24.3 in HCC were determined to be positively correlated with the PRL-3 overexpression. PRL-3 overexpression promoted HCC cell proliferation, migration and adhesion, while its loss had the opposite effects. Further study showed that focal adhesion kinase (FAK) was co-amplified and co-expressed with PRL-3 in HCC. Interestingly, PRL-3 also promoted the phosphorylation of FAK, which subsequently mediated the oncogenic functions of PRL-3 in HCC cells. Moreover, TGFB1 was identified as a downstream molecule of PRL-3. TGF-β signalling was shown to mediate the PRL-3-induced activation of FAK. Furthermore, the p38 and PI3K/AKT pathways were observed to mediate the PRL-3-induced expression of TGFB1 and the subsequent activation of FAK, while the activation of FAK in turn stimulated activation of the p38 and PI3K/AKT pathways, forming a PRL-3-triggered AKT/p38/TGFB1/FAK positive feedback loop. Conclusion: Collectively, our findings indicate that the PTP PRL-3 plays a crucial role in the progression of HCC and provides an example of how co-amplified genes work together in HCC. Ivyspring International Publisher 2020-08-18 /pmc/articles/PMC7481414/ /pubmed/32929353 http://dx.doi.org/10.7150/thno.42069 Text en © The author(s) This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Research Paper
Zhou, Qiming
Zhou, Qianlei
Liu, Qinghua
He, Zhanghai
Yan, Yongcong
Lin, Jianhong
Chen, Zheng
He, Chuanchao
Mao, Kai
Wang, Jie
Zhou, Zhenyu
Xiao, Zhiyu
Zhang, Jianlong
PRL-3 facilitates Hepatocellular Carcinoma progression by co-amplifying with and activating FAK
title PRL-3 facilitates Hepatocellular Carcinoma progression by co-amplifying with and activating FAK
title_full PRL-3 facilitates Hepatocellular Carcinoma progression by co-amplifying with and activating FAK
title_fullStr PRL-3 facilitates Hepatocellular Carcinoma progression by co-amplifying with and activating FAK
title_full_unstemmed PRL-3 facilitates Hepatocellular Carcinoma progression by co-amplifying with and activating FAK
title_short PRL-3 facilitates Hepatocellular Carcinoma progression by co-amplifying with and activating FAK
title_sort prl-3 facilitates hepatocellular carcinoma progression by co-amplifying with and activating fak
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7481414/
https://www.ncbi.nlm.nih.gov/pubmed/32929353
http://dx.doi.org/10.7150/thno.42069
work_keys_str_mv AT zhouqiming prl3facilitateshepatocellularcarcinomaprogressionbycoamplifyingwithandactivatingfak
AT zhouqianlei prl3facilitateshepatocellularcarcinomaprogressionbycoamplifyingwithandactivatingfak
AT liuqinghua prl3facilitateshepatocellularcarcinomaprogressionbycoamplifyingwithandactivatingfak
AT hezhanghai prl3facilitateshepatocellularcarcinomaprogressionbycoamplifyingwithandactivatingfak
AT yanyongcong prl3facilitateshepatocellularcarcinomaprogressionbycoamplifyingwithandactivatingfak
AT linjianhong prl3facilitateshepatocellularcarcinomaprogressionbycoamplifyingwithandactivatingfak
AT chenzheng prl3facilitateshepatocellularcarcinomaprogressionbycoamplifyingwithandactivatingfak
AT hechuanchao prl3facilitateshepatocellularcarcinomaprogressionbycoamplifyingwithandactivatingfak
AT maokai prl3facilitateshepatocellularcarcinomaprogressionbycoamplifyingwithandactivatingfak
AT wangjie prl3facilitateshepatocellularcarcinomaprogressionbycoamplifyingwithandactivatingfak
AT zhouzhenyu prl3facilitateshepatocellularcarcinomaprogressionbycoamplifyingwithandactivatingfak
AT xiaozhiyu prl3facilitateshepatocellularcarcinomaprogressionbycoamplifyingwithandactivatingfak
AT zhangjianlong prl3facilitateshepatocellularcarcinomaprogressionbycoamplifyingwithandactivatingfak